Peer-Reviewed, Prospective Study Confirms Intraosseous Access May
Provide Faster, More Accurate Vascular Access than Central Venous
Catheters for Emergencies Involving Adult Patients
WAYNE, Pa.--(BUSINESS WIRE)--Jul. 29, 2015--
Teleflex Incorporated (NYSE: TFX), a leading global provider of medical
devices for critical care and surgery, announced that newly published
research has documented important advantages of intraosseous vascular
access over central venous catheterization for medical emergencies
involving adult patients.1 The company’s ARROW® EZ-IO® Intraosseous
Vascular Access System was the intraosseous vascular access device used
in the study.
Intraosseous vascular access refers to the process of administering
medications or other fluids into the bone marrow to gain a pathway to
the body’s vascular system. After first being demonstrated in the 1940s,
the process has gained new popularity since guidelines from the American
Heart Association recommended that providers use it when circumstances
make regular intravenous access difficult or impossible.1
This peer‐reviewed article described a clinical study designed to
compare intraosseous vascular access to landmark-guided central venous
catheter (CVC) placement during inpatient medical emergencies at a large
urban teaching hospital. The study was part of a quality improvement
initiative, reporting on intraosseous access for an inpatient rapid
emergency team response. The in-press article appears online in the
respected journal Critical Care Medicine, the official journal of
the Society of Critical Care Medicine.
The study involved 79 adults who received central access between
February 2012 and July 2013. The events investigated included 79 medical
emergency team calls, encompassing 60 non-arrests and 19 cardiac
arrests. Of the 79 patients, 31 received intraosseous access with the
ARROW® EZ-IO® System and 48
received a CVC.
The results demonstrated the benefits of intraosseous access in
emergency circumstances in several ways. First-pass success rates with
intraosseous access were substantially higher than with the CVC: 90.3%
vs. 37.5%. Overall success rates with intraosseous access were superior,
as well, with a rate of 96.8% for the ARROW® EZ-IO® System
and an 81.3% rate for CVC access. CVC placements took significantly
longer than intraosseous access – an average of 10.7 minutes compared to
1.2 minutes for the intraosseous route.
In total, mean attempts to place a CVC per patient were almost three
times higher than intraosseous attempts (2.8 vs 1.1) and more CVC kits
were used on average per patient than intraosseous kits (1.3 vs 1.1).
All of the above results were statistically significant.
“As the market leader in vascular access, we continue to partner with
clinicians to expand their options for vascular access,” said Jay White,
President of the Teleflex Vascular Access Division. “Our full line of
vascular access solutions provides clinicians with the ability to select
the right line for the right patient at the right time, optimizing
patient outcomes. This study has done an excellent job demonstrating the
benefits of the ARROW® EZ-IO® System during
inpatient medical emergencies.”
The ARROW® EZ-IO® System was also discussed in a
literature review published last year in Journal of Clinical
Anesthesia. The author, Jonathan A. Anson, M.D., suggests a
framework for incorporating intraosseous technique into clinical
anesthesia practice and compares currently available technologies. One
of the studies described in the review is a seven-year retrospective
analysis showing that the battery-powered ARROW® EZ-IO®
System had a much greater first-attempt success rate (96%) than either a
leading impact-driven device (55%) or a manual technique (50%). Other
studies included in the review found similar results for the ARROW®EZ-IO® System versus the impact-driven system
and also demonstrated that the ARROW® EZ-IO® was
easy to learn and use.
Overall in the studies cited in the review, the ARROW® EZ-IO® System
had a greater insertion success rate than either of the two leading
impact-driven devices. It also had a substantially faster mean insertion
time (60 sec.) than the other two devices (86 sec. and 101 sec.) In
three prospective studies described in the review involving a total of
130 patients, no infections occurred.2
Additional information on the ARROW® EZ-IO® System
can be found at www.teleflex.com.
Clinical education resources on the technology can be viewed at www.teleflex.com/en/usa/ezioeducation/index.html.
About Teleflex Incorporated
Teleflex is a leading global provider of specialty medical devices for a
range of procedures in critical care and surgery. Our mission is to
provide solutions that enable healthcare providers to improve outcomes
and enhance patient and provider safety. Headquartered in Wayne, PA,
Teleflex employs approximately 12,200 people and serves healthcare
providers worldwide. For additional information about Teleflex please
refer to www.teleflex.com.
Forward-Looking Statements
Any statements contained in this press release that do not describe
historical facts may constitute forward-looking statements. Any
forward-looking statements contained herein are based on our
management's current beliefs and expectations, but are subject to a
number of risks, uncertainties and changes in circumstances, which may
cause actual results or company actions to differ materially from what
is expressed or implied by these statements. These risks and
uncertainties are identified and described in more detail in our filings
with the Securities and Exchange Commission, including our Annual Report
on Form 10-K.
Teleflex, Arrow, and EZ-IO are trademarks or registered trademarks of
Teleflex Incorporated or its affiliates.
© 2015 Teleflex Incorporated. All rights reserved. MC-001511
References:
1. Lee PM, Lee C, Rattner P, Wu X, et al. Intraosseous versus central
venous catheter utilization and performance during inpatient medical
emergencies. Crit Care Med, 2015;43(6):1233-38.
2. Anson JA. Vascular access in resuscitation: Is there a role
for the intraosseous route? Anesthesiology 2014;120(4)1015-31.
View source version on businesswire.com: http://www.businesswire.com/news/home/20150729005016/en/
Source: Teleflex Incorporated
Teleflex Incorporated
Jake Elguicze
Treasurer and Vice
President, Investor Relations
610-948-2836
jake.elguicze@teleflex.com
www.teleflex.com